Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$1,057.02 5.99 (0.57%) as of 4:30 Mon 7/1


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 110.66(B)
Last Volume: 383,195 Avg Vol: 759,306
52 Week Range: $692.45 - $1071.19
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 192,108 255,165 311,759 469,743
Total Sell Value $188,697,290 $247,812,013 $294,950,701 $405,465,351
Total People Sold 7 14 16 18
Total Sell Transactions 18 43 67 128
End Date 2024-03-31 2023-12-29 2023-06-30 2022-06-30

   
Records found: 2430
  Page 58 of 98  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Goldberg Murray A SVP Administration & Asst Secr   •       –      –    2014-02-24 4 OE $52.03 $1,961,746 D/D 30,227 77,475     -
   Gilman Alfred G Director   –       •      –    2014-02-21 4 AS $340.00 $1,700,000 D/D (5,000) 0     -
   Gilman Alfred G Director   –       •      –    2014-02-21 4 OE $18.61 $93,050 D/D 5,000 5,000     -
   Sing George L Director   –       •      –    2014-02-21 4 S $338.00 $5,085,000 D/D (15,000) 112,772     -
   Sing George L Director   –       •      –    2014-02-21 4 OE $15.80 $237,000 D/D 15,000 117,772     -
   Goldberg Murray A SVP Administration & Asst Secr   •       –      –    2014-02-21 4 AS $327.84 $7,153,608 D/D (21,258) 63,102     -
   Goldberg Murray A SVP Administration & Asst Secr   •       –      –    2014-02-20 4 D $326.05 $9,583,914 D/D (29,394) 84,360     -
   Goldberg Murray A SVP Administration & Asst Secr   •       –      –    2014-02-20 4 OE $30.63 $2,420,805 D/D 50,652 85,891     -
   Goldstein Joseph L Director   –       •      –    2014-02-20 4 S $326.96 $326,989 D/D (1,000) 1,000     -
   Mccorkle Douglas S VP Controller and Asst Treasur   •       –      –    2014-02-20 4 OE $21.25 $63,750 D/D 3,000 3,000     -
   Terifay Robert J SVP Commercial   •       –      –    2014-02-18 4 S $331.66 $4,279,893 D/D (12,865) 20,029     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2014-02-18 4 AS $324.81 $1,209,036 D/D (3,648) 15,600     -
   Sing George L Director   –       •      –    2014-02-14 4 S $324.00 $4,860,000 D/D (15,000) 112,772     -
   Sing George L Director   –       •      –    2014-02-14 4 OE $9.17 $137,550 D/D 15,000 127,772     -
   Terifay Robert J SVP Commercial   •       –      –    2014-02-14 4 D $323.30 $4,826,869 D/D (14,930) 32,894     -
   Terifay Robert J SVP Commercial   •       –      –    2014-02-14 4 OE $21.25 $590,644 D/D 27,795 47,824     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2014-02-14 4 D $323.30 $1,245,352 D/D (3,852) 19,248     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2014-02-14 4 OE $30.63 $229,725 D/D 7,500 23,100     -
   Yancopoulos George President Regeneron Laboratori   •       •      –    2014-02-13 4 GA $0.00 $0 I/I 568,343 568,343     -
   Yancopoulos George President Regeneron Laboratori   •       •      –    2014-02-13 4 GD $0.00 $0 D/D 568,343 500,000     -
   Stahl Neil SVP Research and Development S   •       –      –    2014-02-13 4 S $316.55 $7,209,136 D/D (22,612) 24,391     -
   Goldstein Joseph L Director   –       •      –    2014-02-12 4 S $320.62 $320,620 D/D (1,000) 2,000     -
   Shooter Eric M Director   –       •      –    2014-02-12 4 GD $0.00 $0 I/I 7,000 0     -
   Shooter Eric M Director   –       •      –    2014-02-12 4 A $0.00 $0 I/I 7,000 7,000     -
   Shooter Eric M Director   –       •      –    2014-02-12 4 S $320.41 $4,807,869 D/D (15,000) 0     -
  2430 Records found
  Previous  50  51  52  53  54  55  56  57  58  59  Next   
  Page 58 of 98
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us